Peripheral blood gamma-delta T cells in advanced-stage cancer patients

Basit Öğe Kaydı
dc.authorid0000-0003-1493-4579en_US
dc.authorid0000-0002-2226-124Xen_US
dc.authorid0000-0002-4075-6692en_US
dc.authorid0000-0003-3550-9993en_US
dc.contributor.authorBilgi, Oğuz
dc.contributor.authorKaragöz, Bülent
dc.contributor.authorKandemir, E. Gökhan
dc.contributor.authorÖztürk, Ahmet
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorYaylacı, Mustafa
dc.date.accessioned2024-07-12T21:01:19Z
dc.date.available2024-07-12T21:01:19Z
dc.date.issued2008en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractGamma-delta T (?? T) cells form a subgroup which has been reported to play a role in both natural and acquired immunity. Their levels have been found to increase in some tumour tissues. The aim of this study was to investigate the ratio of ?? T cells to all T cells in the peripheral blood of advanced-stage cancer patients; the level of ?? T cells expressing the V?2-T-cell receptor (TCR) chain; NKG2D receptor expression; and apoptotic (Annexin-V) ?? T-cell levels. Twenty patients with advanced-stage cancer and 13 healthy controls were included. No statistical differences were found between control and patient groups in terms of the ?? T/total T-cell ratio (P=0.53), the V?2-TCR expressing ?? T-cell ratio (P=0.19) or the Annexin-V ratio (P=0.48). However, NKG2D expression in ?? T cells was significantly different between the control and patient groups (P=0.014). In summary it was shown that the levels of NKG2D receptors, which are responsible for the cytolytic effect of ?? T cells, were lower in cancer patients than in healthy adults. However, no significant differences were observed in the other parameters studied between groups.en_US
dc.identifier.citationBilgi, O., Karagoz, B., Turken, O., Kandemir, E. G., Ozturk, A., Gumus, M. ve Yaylaci, M. (2008). Peripheral blood gamma-delta T cells in advanced-stage cancer patients. Advances in therapy, 25(3), 218–224. https://doi.org/10.1007/s12325-008-0032-zen_US
dc.identifier.endpage224en_US
dc.identifier.issn0741-238X
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage218en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s12325-008-0032-z
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3489
dc.identifier.volume25en_US
dc.institutionauthorTürken, Orhan
dc.language.isoenen_US
dc.publisherSpringer Linken_US
dc.relation.ispartofAdvances in Therapyen_US
dc.relation.isversionof10.1007/s12325-008-0032-z.en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00108
dc.subjectgamma-delta cellen_US
dc.subjectimmunityen_US
dc.subjectT cellen_US
dc.titlePeripheral blood gamma-delta T cells in advanced-stage cancer patientsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu